Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564405 | 0.88 | NPC1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2085740 | 0.86 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31661203 | 0.84 | MAOB (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2728294 | 0.84 | MAOB (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL914727 | 0.84 | MAOB (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2728922 | 0.84 | MAOB (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL743289 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2317769 | 0.83 | MAOB (0.52) | CA12CA2CA7CA9CA14 | |
| SCHEMBL743821 | 0.83 | ALDH1A1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26131863 | 0.81 | MAOB (0.50) | MIFPFKFB3MAOBMAOAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214976-A1 | GPR35 MODULATORS AND USES THEREOF | CROSSIGNAL THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4504712-A1 | GPR35 MODULATORS AND USES THEREOF | Crossignal Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119137105-A | GPR35 modulators and uses thereof | 交信医药研发公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023196538-A1 | GPR35 MODULATORS AND USES THEREOF | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-2125782-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | CA12 3133/4885CA1 3462/4885CA2 1207/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | CA12 3133/4885CA1 3462/4885CA2 1207/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CA12 4833/4885CA1 4798/4885CA2 4723/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | CA12 4473/4885CA1 4563/4885CA2 3527/4885 |
| US-20250214976-A1 | GPR35 MODULATORS AND USES THEREOF | GPR35, GPR34, GPR68 | CA12 1318/4885CA1 1747/4885CA2 1999/4885 |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | CA12 538/4885CA1 1011/4885CA2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.